-
公开(公告)号：EP4436670A1
公开(公告)日：2024-10-02
申请号：EP22822068.7
申请日：2022-11-24
发明人： MARTIN-VILLALBA, Ana , BRÜGGER, Britta , VATTULAINEN, Ilpo , LOLICATO, Fabio , GÜLCÜLER, Gülce Sila , KLEBER, Susanne
IPC分类号： A61P35/00 , C07K14/715
CPC分类号： A61P35/00 , C07K2319/0320130101 , C07K14/7151
-
2.发明授权INHIBITION OF THE CD95 LIGAND/RECEPTOR SYSTEM FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND INJURIES 有权CD95配体/受体系统的抑制神经系统疾病和损伤的治疗
公开(公告)号：EP1592446B1
公开(公告)日：2008-05-07
申请号：EP04709605.2
申请日：2004-02-10
IPC分类号： A61K39/395 , A61K38/17 , A61K31/7088 , A61P25/02 , A61P25/28
CPC分类号： C07K16/2875 , A61K39/39541 , A61K2039/505 , A61K2300/00
摘要： The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal, particularly for the treatment of spinal cord injury, more particularly for the treatment of paraplegia.
-
3.发明授权KOMBINATION VON VERBINDUNGEN, WELCHE DIE BIOLOGISCHEN WIRKUNGEN VON TNF-ALPHA UND CD95L HEMMEN, IN EINEM ARZNEIMITTEL 有权组合的化合物的其中在药物TNF-α和CD95L INHIBIT的生物效应
公开(公告)号：EP1235592B1
公开(公告)日：2007-11-14
申请号：EP00993306.0
申请日：2000-12-06
IPC分类号： A61K39/395 , A61P9/10 , A61P25/28
CPC分类号： C07K16/241 , A61K2039/505 , C07K16/2875
摘要： The invention relates to medicaments that contain one or more compounds that inhibit the biological effects of TNF- alpha and CD95L, for example by blocking the binding of said ligands to their natural receptors, thereby blocking signal transduction. The preferred compounds are neutralizing anti-TNF alpha antibodies and neutralizing anti-CD95L antibodies. The invention further relates to the use of the inventive compounds for preventing or treating strokes or heart attacks.
-
4.发明公开INHIBITION OF THE CD95 LIGAND/RECEPTOR SYSTEM FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND INJURIES 有权CD95配体/受体系统的抑制神经系统疾病和损伤的治疗
公开(公告)号：EP1592446A1
公开(公告)日：2005-11-09
申请号：EP04709605.2
申请日：2004-02-10
IPC分类号： A61K39/395 , A61K38/17 , A61K31/7088 , A61P25/02 , A61P25/28
CPC分类号： C07K16/2875 , A61K39/39541 , A61K2039/505 , A61K2300/00
摘要： The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal, particularly for the treatment of spinal cord injury, more particularly for the treatment of paraplegia.
-
5.发明授权NEUTRALIZATION OF CD95 ACTIVITY BLOCKS INVASION OF GLIOBLASTOMA CELLS IN VIVO 有权中和CD95的作用在体内阻断胶质母细胞瘤细胞的侵袭
公开(公告)号：EP2101877B1
公开(公告)日：2013-06-19
申请号：EP07857153.6
申请日：2007-12-28
申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Universitätsklinikum Heidelberg
发明人： MARTIN-VILLALBA, Ana , KLEBER, Susanne , WIESTLER, Benedikt , KRAMMER, Peter, G. , HEROLD-MENDE, Christel , SANCHO-MARTINEZ, Ignacio
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61K38/17 , A61K31/7088
CPC分类号： C07K16/2875 , A61K38/00 , A61K2039/505 , C07K14/70575 , C07K14/70578 , C07K16/2878 , C07K2317/76 , C07K2319/00 , C07K2319/30 , G01N33/566 , G01N33/57407 , G01N33/6863 , G01N2333/70578 , G01N2500/00 , G01N2500/04 , G01N2500/10 , G01N2510/00
摘要： The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
-
6.发明公开NEUTRALIZATION OF CD95 ACTIVITY BLOCKS INVASION OF GLIOBLASTOMA CELLS IN VIVO 有权中和CD95的作用在体内阻断胶质母细胞瘤细胞的侵袭
公开(公告)号：EP2101877A2
公开(公告)日：2009-09-23
申请号：EP07857153.6
申请日：2007-12-28
申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Universitätsklinikum Heidelberg
发明人： MARTIN-VILLALBA, Ana , KLEBER, Susanne , WIESTLER, Benedikt , KRAMMER, Peter, G. , HEROLD-MENDE, Christel , SANCHO-MARTINEZ, Ignacio
IPC分类号： A61P35/00 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2875 , A61K38/00 , A61K2039/505 , C07K14/70575 , C07K14/70578 , C07K16/2878 , C07K2317/76 , C07K2319/00 , C07K2319/30 , G01N33/566 , G01N33/57407 , G01N33/6863 , G01N2333/70578 , G01N2500/00 , G01N2500/04 , G01N2500/10 , G01N2510/00
摘要： The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
-
7.发明公开USE OF CD95 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS 审中-公开VERWENDUNG EINES CD95-INHIBITORS ZUR BEHANDLUNG VONENTZÜNDLICHENERKRANKUNGEN
公开(公告)号：EP2318441A2
公开(公告)日：2011-05-11
申请号：EP09777196.8
申请日：2009-07-14
IPC分类号： C07K16/28 , C07K14/705 , A61P29/00 , A61P25/00
CPC分类号： C07K16/2875 , A61K38/00 , A61K2039/505 , C07K14/70575
摘要： The present invention refers to the use of an inhibitor of the CD95/CD95L system for the prevention and/or treatment of an inflammatory disorder or for the prevention and/or treatment of an inflammatory process in a neuronal disorder, particularly in a CNS disorder.
摘要翻译： 本发明涉及CD95 / CD95L系统的抑制剂用于预防和/或治疗炎性病症或预防和/或治疗神经元病症，特别是CNS病症中的炎性过程的用途。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.011 秒)
